Adagio Therapeutics Reports That None of the Mutations Present in SARS-CoV-2 Variant, Omicron, Are Associated with Escape from ADG20 Neutralization In Vitro
Additional in vitro studies to determine neutralization activity of ADG20 against Omicron are ongoing ADG20 EUA submissions planned for prevention